Case Control Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Dec 28, 2021; 27(48): 8343-8356
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8343
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Receiver operating characteristic curves of the combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein as compared to squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in predicting two-year mortality in the estimation cohort. The clinical relevance of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in patients with cirrhosis was determined by the calculation of the area under the receiver operating characteristic. Baseline serum levels distribution above the cut-off of the two biomarkers in patients who developed hepatocellular carcinoma vs patients who did not was compared. AUROC, area under the receiver operating characteristic. Comparison of the AUROCs estimated for each set. AFP: Alpha-fetoprotein; SCCA-IgM: Squamous cell carcinoma antigen immunocomplex.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Estimating two- and five-year hepatocellular carcinoma disease-free survival by using Kaplan-Meier method according to the squamous cell carcinoma antigen immunocomplex, alpha-fetoprotein and combination of those in estimation cohort. A: Squamous cell carcinoma antigen immunocomplex (SCCA-IgM); low-risk: < 124 AU/mL, high-risk: > 124 AU/mL; B: Alpha-fetoprotein (AFP); low-risk: < 5 ng/mL, high-risk: > 5 ng/mL; C: Combination of SCCA-IgM and AFP. AFP: Alpha-fetoprotein; SCCA-IgM: Squamous cell carcinoma antigen immunocomplex.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Estimating two- and five-year hepatocellular carcinoma disease-free survival by using Kaplan-Meier method according to the squamous cell carcinoma antigen immunocomplex, alpha-fetoprotein and combination of those both in validation cohort. A: Squamous cell carcinoma antigen immunocomplex (SCCA-IgM); low-risk: < 124 AU/mL, high-risk: > 124 AU/mL; B: Alpha-fetoprotein (AFP); low-risk: < 5 ng/mL, high-risk: > 5 ng/mL; C: Combination of SCCA-IgM and AFP. AFP: Alpha-fetoprotein; SCCA-IgM: Squamous cell carcinoma antigen immunocomplex.